Chlamydophila pneumoniae

Infectious Disease Clinics of North America

Volumn 24, Issue 1, 2010, Pages 61-71

  Burillo, Almudena ^a   Bouza, Emilio ^b,c,d  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Chlamydophila pneumoniae; Diagnosis; Pneumonia; Treatment

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR OUTER MEMBRANE PROTEIN; MOXIFLOXACIN; OFLOXACIN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 2; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY TITER; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BRONCHITIS; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTRON MICROSCOPY; ENZYME IMMUNOASSAY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INCIDENCE; INCUBATION TIME; LARYNGITIS; NONHUMAN; PHARYNGITIS; POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE HOMOLOGY; SINUSITIS; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; GUIDELINES AS TOPIC; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NASOPHARYNX; PNEUMONIA, BACTERIAL; UNITED STATES;

EID: 76549111356     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.10.002     Document Type: Review

References (67)

1. Essig A. Chlamydia and Chlamydophila. In: Murray P.R., Baron E.J., Jorgensen J.H., et al. (Eds). Manual of clinical microbiology. 9th edition (2007), ASM, Washington, DC 1021
2. Grayston J.T., Aldous M.B., Easton A., et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 168 (1993) 1231
3. Sopena N., Pedro-Botet M.L., Sabria M., et al. Comparative study of community-acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae. Scand J Infect Dis 36 (2004) 330
4. Andraws R., Berger J.S., and Brown D.L. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293 (2005) 2641
5. de Barbeyrac B., and Bebear C. [Chlamydial pathogenesis: diagnostic and therapeutic consequences]. Arch Pediatr 12 (2005) S26 [in French]
6. Kuppuswamy V.C., and Gupta S. Antibiotic therapy for coronary heart disease: the myth and the reality. Timely Top Med Cardiovasc Dis 10 (2006) E2
7. Saikku P., Leinonen M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2 (1988) 983
8. West S.K., Kohlhepp S.J., Jin R., et al. Detection of circulating Chlamydophila pneumoniae in patients with coronary artery disease and healthy control subjects. Clin Infect Dis 48 (2009) 560
9. Greenlee J.E., and Rose J.W. Controversies in neurological infectious diseases. Semin Neurol 20 (2000) 375
10. Horvath Z., and Vecsei L. [The significance of Chlamydia pneumoniae in selected neurologic disorders]. Ideggyogy Sz 59 (2006) 4 [in Hungarian]
11. Moses Jr. H., and Sriram S. An infectious basis for multiple sclerosis: perspectives on the role of Chlamydia pneumoniae and other agents. BioDrugs 15 (2001) 199
12. Sriram S., Ljunggren-Rose A., Yao S.Y., et al. Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. J Infect Dis 192 (2005) 1219
13. Swanborg R.H., Whittum-Hudson J.A., and Hudson A.P. Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis-a critical review. Microbes Infect 4 (2002) 1327
14. Swanborg R.H., Whittum-Hudson J.A., and Hudson A.P. Infectious agents and multiple sclerosis-Are Chlamydia pneumoniae and human herpes virus 6 involved?. J Neuroimmunol 136 (2003) 1
15. Johnston S.L., Blasi F., Black P.N., et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354 (2006) 1589
16. Little F.F. Treating acute asthma with antibiotics-not quite yet. N Engl J Med 354 (2006) 1632
17. Baird P.N., Robman L.D., Richardson A.J., et al. Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 17 (2008) 1299
18. Chia J.K., and Chia L.Y. Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis 29 (1999) 452
19. King Jr. L.E., Stratton C.W., and Mitchell W.M. Chlamydia pneumoniae and chronic skin wounds: a focused review. J Investig Dermatol Symp Proc 6 (2001) 233
20. Blasi F., Tarsia P., and Aliberti S. Chlamydophila pneumoniae. Clin Microbiol Infect 15 (2009) 29
21. Stephens R.S., Kalman S., Lammel C., et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282 (1998) 754
22. Grayston J.T., Kuo C.C., Wang S.P., et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 315 (1986) 161
23. Kern J.M., Maass V., and Maass M. Molecular pathogenesis of chronic Chlamydia pneumoniae infection: a brief overview. Clin Microbiol Infect 15 (2009) 36
24. Chedid M.B., Chedid M.F., Ilha D.O., et al. Community-acquired pneumonia by Chlamydophila pneumoniae: a clinical and incidence study in Brazil. Braz J Infect Dis 11 (2007) 75
25. Reechaipichitkul W., Saelee R., and Lulitanond V. Prevalence and clinical features of Chlamydia pneumoniae pneumonia at Srinagarind Hospital, Khon Kaen, Thailand. Southeast Asian J Trop Med Public Health 36 (2005) 151
26. Marston B.J., Plouffe J.F., File Jr. T.M., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157 (1997) 1709
27. Phares C.R., Wangroongsarb P., Chantra S., et al. Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, and Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand. Clin Infect Dis 45 (2007) e147
28. Arnold F.W., Summersgill J.T., Lajoie A.S., et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 175 (2007) 1086
29. Gupta S.K., and Sarosi G.A. The role of atypical pathogens in community-acquired pneumonia. Med Clin North Am 85 (2001) 1349
30. Cunha B.A. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 12 (2006) 12
31. Ekman M.R., Grayston J.T., Visakorpi R., et al. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis 17 (1993) 420
32. Johnson D.H., and Cunha B.A. Atypical pneumonias. Clinical and extrapulmonary features of Chlamydia, Mycoplasma, and Legionella infections. Postgrad Med 93 (1993) 69
33. Wadowsky R.M., Castilla E.A., Laus S., et al. Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. J Clin Microbiol 40 (2002) 637
34. Kauppinen M.T., Saikku P., Kujala P., et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51 (1996) 185
35. Daian C.M., Wolff A.H., and Bielory L. The role of atypical organisms in asthma. Allergy Asthma Proc 21 (2000) 107
36. Feldman C. Pneumonia in the elderly. Med Clin North Am 85 (2001) 1441
37. Emre U., Bernius M., Roblin P.M., et al. Chlamydia pneumoniae infection in patients with cystic fibrosis. Clin Infect Dis 22 (1996) 819
38. Miller S.T., Hammerschlag M.R., Chirgwin K., et al. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 118 (1991) 30
39. Heinemann M., Kern W.V., Bunjes D., et al. Severe Chlamydia pneumoniae infection in patients with neutropenia: case reports and literature review. Clin Infect Dis 31 (2000) 181
40. Cosentini R., Blasi F., Raccanelli R., et al. Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae. Respiration 63 (1996) 61
41. Cunha B.A., and Ortega A.M. Atypical pneumonia. Extrapulmonary clues guide the way to diagnosis. Postgrad Med 99 (1996) 123
42. Kauppinen M.T., Lahde S., and Syrjala H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med 156 (1996) 1851
43. McConnell Jr. C.T., Plouffe J.F., File T.M., et al. Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study. Radiology 192 (1994) 819
44. Kumar S., and Hammerschlag M.R. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 44 (2007) 568
45. Bartlett J.G. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis 47 (2008) S232
46. Hvidsten D., Halvorsen D.S., Berdal B.P., et al. Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling. Clin Microbiol Infect 15 (2009) 42
47. Dowell S.F., Peeling R.W., Boman J., et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 33 (2001) 492
48. Wang S. The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation. J Infect Dis 181 Suppl 3 (2000) S421
49. Peeling R.W., Wang S.P., Grayston J.T., et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 181 Suppl 3 (2000) S426
50. Campbell L.A., Perez Melgosa M., Hamilton D.J., et al. Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol 30 (1992) 434
51. Tong C.Y., and Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 46 (1993) 313
52. Gaydos C.A., Quinn T.C., and Eiden J.J. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol 30 (1992) 796
53. Madico G., Quinn T.C., Boman J., et al. Touchdown enzyme time release-PCR for detection and identification of Chlamydia trachomatis, C. pneumoniae, and C. psittaci using the 16S and 16S-23S spacer rRNA genes. J Clin Microbiol 38 (2000) 1085
54. Nolte F.S. Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. Clin Infect Dis 47 (2008) S123
55. Oosterheert J.J., van Loon A.M., Schuurman R., et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 41 (2005) 1438
56. Thom D.H., Grayston J.T., Campbell L.A., et al. Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients. Eur J Clin Microbiol Infect Dis 13 (1994) 785
57. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27
58. Lipsky B.A., Tack K.J., Kuo C.C., et al. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med 89 (1990) 722
59. Block S., Hedrick J., Hammerschlag M.R., et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 14 (1995) 471
60. Roblin P.M., Montalban G., and Hammerschlag M.R. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrobial Agents Chemother 38 (1994) 1588
61. Harris J.A., Kolokathis A., Campbell M., et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 17 (1998) 865
62. Roblin P.M., and Hammerschlag M.R. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrobial Agents Chemother 42 (1998) 194
63. Hammerschlag M.R., and Roblin P.M. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 15 (2000) 149
64. Hammerschlag M.R., Chirgwin K., Roblin P.M., et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14 (1992) 178
65. Robenshtok E., Shefet D., Gafter-Gvili A., et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 1 (2008) CD004418
66. Bratzler D.W., Ma A., and Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 47 Suppl 3 (2008) S193
67. Nicks B.A., Manthey D.E., and Fitch M.T. The Centers for Medicare and Medicaid Services (CMS) community-acquired pneumonia core measures lead to unnecessary antibiotic administration by emergency physicians. Acad Emerg Med 16 (2009) 184